US 12,304,913 B2
Dihydropyrrolopyrazole derivative
Noriaki Iwase, Ube (JP); Yasuhiro Aga, Ube (JP); Shigeyuki Kono, Ube (JP); and Tomio Kimura, Ube (JP)
Assigned to UBE INDUSTRIES, LTD., Ube (JP)
Appl. No. 17/293,873
Filed by UBE INDUSTRIES, LTD., Ube (JP)
PCT Filed Nov. 13, 2019, PCT No. PCT/JP2019/044558
§ 371(c)(1), (2) Date May 13, 2021,
PCT Pub. No. WO2020/100944, PCT Pub. Date May 22, 2020.
Claims priority of application No. 2018-213807 (JP), filed on Nov. 14, 2018.
Prior Publication US 2022/0002303 A1, Jan. 6, 2022
Int. Cl. C07D 487/04 (2006.01); A61P 35/00 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 35/00 (2018.01)] 17 Claims
 
1. A compound or a pharmacologically acceptable salt thereof, wherein the compound is of formula (I):

OG Complex Work Unit Chemistry
wherein:
each R together with the carbon atom to which they are attached form a cyclobutyl group or a cyclopropyl group;
R1, R2, and R3 are each independently a substituted or unsubstituted linear or branched C1-4 alkyl group;
A is a substituted or unsubstituted C6-10 aryl group or a substituted or unsubstituted heteroaryl group;
Z is a hydrogen atom or a substituted or unsubstituted C1-6 alkyl group; or
A and Z are bonded together with the nitrogen atom to which they are attached to form a substituted or unsubstituted bicyclic fused heteroaryl group.